

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF CALIFORNIA**

CHAYLA CLAY *et al.*,  
Plaintiffs,  
v.  
CYTOSPORT, INC.,  
Defendant.

Case No: 3:15-cv-00165-L- AGS

**CLASS ACTION**

**ORDER (1) GRANTING IN PART  
AND DENYING IN PART  
PLAINTIFFS' MOTION FOR  
CLASS CERTIFICATION; AND  
(2) GRANTING IN PART AND  
DENYING IN PART  
DEFENDANT'S MOTION TO  
EXCLUDE EXPERT TESTIMONY**

Pending before the Court is Plaintiffs' motion for class action certification. Defendant filed an opposition, and Plaintiffs replied. As part of opposition to Plaintiffs' motion, Defendant filed a motion to exclude the testimony of Plaintiffs' expert Elizabeth Howlett, Ph.D. Plaintiffs opposed the motion and Defendant replied.<sup>1</sup> This matter is submitted on the briefs pursuant to Civil Local Rule 7.1.d.1. For the reasons which follow, Plaintiffs' motion for class certification is granted in part. Defendant's motion to exclude Dr. Howlett's testimony is granted in part for purposes of class certification only.

---

<sup>1</sup> Not counting exhibits which were filed non-electronically and several motions to file documents under seal, the parties filed in excess of 4,000 pages of briefing and exhibits.

1 **I. BACKGROUND**

2 Plaintiffs are consumers who purchased Defendant's protein shake and/or  
3 protein powder products. They allege that (1) the Nutrition Facts panel and  
4 packaging of some of Defendant's ready-to-drink protein shake products overstated  
5 the amount of protein content; (2) the Ingredients section on the labels of their  
6 Muscle Milk protein powder products included amino acid L-glutamine, L-  
7 glutamine was also listed as an ingredient of the "Precision Protein Blend"  
8 elsewhere on the labels, and an L-glutamine molecule was shown on a chart of the  
9 amino acid profile for some of the products, implying that L-glutamine was  
10 included in its unbonded form, when none was included; and (3) prominently  
11 displaying on its Muscle Milk protein powder packaging that the product was  
12 "lean" or contained a special blend of "Lean Lipids," when the products contained  
13 oils and were no leaner than other protein powders on the market which were not  
14 marketed as "lean."

15 Plaintiffs contend that Defendant's product labeling is false and misleading  
16 in violation of California, Florida and Michigan state consumer protection laws.  
17 After Defendant's summary judgment motion was granted in part, the following  
18 claims remain: violation of California False Advertising Law, Cal. Bus. & Prof.  
19 Code §§ 17500 *et seq.* ("FAL"); violation of California Consumer Legal Remedies  
20 Act, Cal. Civ. Code §§ 1750 ("CLRA"); violation of California Unfair Competition  
21 Law, Cal. Bus. & Prof. Code §§ 17200 *et seq.* ("UCL"); violation of Florida  
22 Deceptive and Unfair Trade Practices Act, Fla. Stat. §§ 501.201 *et seq.*  
23 ("FDUTPA"); violation of Michigan Consumer Protection Act, Mich. Comp. Laws  
24 § 445.903(1)(c) ("MCPA"); and breach of express warranty under California  
25 Uniform Commercial Code - Sales, Cal. Com. Code § 2313. Plaintiffs seek,  
26 among other remedies, injunctive relief and restitution.

27 /////  
28

1 Plaintiffs move for class action certification under Federal Rule of Civil  
2 Procedure 23(b)(3). They seek to certify two nationwide classes, one for the  
3 purchasers of Defendant's liquid shakes, and the other for protein powder  
4 purchasers defined as follows:

5 All persons in the United States who, within four (4) years of the  
6 filing of this Complaint, purchased Defendant's Cytosport Whey  
7 Isolate Protein Drink; Monster Milk: Protein Power Shake; Genuine  
8 Muscle Milk: Protein Nutrition Shake; and Muscle Milk Pro Series  
40: Mega Protein Shake.

9 All persons in the United States who, within four (4) years of the  
10 filing of this Complaint, purchased Defendant's Muscle Milk: Lean  
11 Muscle Protein Powder; Muscle Milk Light: Lean Muscle Protein  
12 Powder; Muscle Milk Naturals: Nature's Ultimate Lean Muscle  
13 Protein; Muscle Milk Gainer; and High Protein Gainer Powder Drink  
14 Mix; Muscle Milk Pro Series 50: Lean Muscle Mega Protein Powder  
(14 oz. to 10 lbs. products); and the [*sic*] size Monster Milk: Lean  
Muscle Protein Supplement (2.06 and 4.13 lbs. products).

15 (Doc. no. 157 (notice of mot.) at 2.)<sup>2</sup> Plaintiffs request that the nationwide classes  
16 be certified for UCL and FAL violations. (*Id.*)

17 Plaintiffs also move for certification of subclasses for California, Florida and  
18 Michigan residents under each state's consumer protection statutes, as well as the  
19 Magnuson-Moss Warranty Act, 15 U.S.C. §§2301 *et seq.* ("MMWA"). (Doc. no.  
20 157 at 2-4.) Like the nationwide classes, there are two subclasses for each state,  
21 one for the liquid shake purchasers and the other for protein powder purchasers.  
22 The respective lists of relevant products are the same as for the nationwide classes.  
23 (*See id.* at 3-4.)

24 //

---

27 <sup>2</sup> With the exception of deposition transcripts, all page references in citations  
28 to docketed documents are to the page numbers assigned by the ECF system.

1 **II. DISCUSSION**

2 "The class action is an exception to the usual rule that litigation is conducted  
3 by and on behalf of the individual named parties only." *Wal-Mart Stores, Inc. v.*  
4 *Dukes*, 564 U.S. 338, 348 (2011) (internal quotation marks and citation omitted).  
5 A party seeking class certification must be prepared to prove that it meets the  
6 requirements of Federal Rule of Civil Procedure 23(a) and the requirements of at  
7 least one of the categories under Rule 23(b). *Comcast Corp. v. Behrend*, 569 U.S.  
8 27, 33 (2013).

9 The district court must conduct a rigorous analysis to determine whether  
10 these prerequisites of Rule 23 have been met. *Gen. Tel. Co. v. Falcon*, 457 U.S.  
11 147, 161 (1982). The moving party "must . . . satisfy through evidentiary proof"  
12 Rule 23 requirements. *Comcast*, 569 U.S. at 33. Accordingly, "the class  
13 determination generally involves considerations that are enmeshed in the factual  
14 and legal issues comprising the plaintiff's cause of action," *Coopers & Lybrand v.*  
15 *Livesay*, 437 U.S. 463, 469 (1978) (internal quotation marks and citation omitted),  
16 and it "may be necessary for the court to probe behind the pleadings before coming  
17 to rest on the certification question," *Falcon*, 457 U.S. at 160, which may "entail  
18 some overlap with the merits of the plaintiff's underlying claim," *Dukes*, 564 U.S.  
19 at 351. If a court is not fully satisfied that the requirements of Rules 23(a) and (b)  
20 are met, certification should be denied. *Id.* at 161. However, "Rule 23 grants  
21 courts no license to engage in free-ranging merits inquiries at the certification  
22 stage. Merits questions may be considered to the extent—but only to the extent—  
23 that they are relevant to determining whether the Rule 23 prerequisites for class  
24 certification are satisfied." *Amgen Inc. v. Conn. Ret. Plans and Trust Funds*, 568  
25 U.S 455, 466 (2013).

26 /////

27  
28

1           **A. Rule 23(a) Requirements**

2           "Rule 23(a) ensures that the named plaintiff is an appropriate representative  
3 of the class whose claims he or she wishes to litigate. The Rule's four  
4 requirements – numerosity, commonality, typicality, and adequate representation –  
5 effectively limit the class claims to those fairly encompassed by the named  
6 plaintiff's claims." *Dukes*, 564 U.S. at 349 (internal quotation marks and citations  
7 omitted). "A party seeking class certification must affirmatively demonstrate his  
8 compliance with the Rule – that is, she or he must be prepared to prove that there  
9 are *in fact* sufficiently numerous parties, common questions of law or fact, etc."  
10 *Id.* at 350 (emphasis in original).

11                   **1. Numerosity**

12           Rule 23(a)(1) requires the class to be "so numerous that joinder of all  
13 members is impracticable." Fed. R. Civ. P. 23(a)(1); *Staton v. Boeing Co.*, 327  
14 F.3d 938, 953 (9th Cir. 2003). The plaintiff need not state the exact number of  
15 potential class members; nor is a specific minimum number required. *Arnold v.*  
16 *United Artists Theatre Circuit, Inc.*, 158 F.R.D. 439, 448 (N.D. Cal. 1994). Rather,  
17 whether joinder is impracticable depends on the facts and circumstances of each  
18 case. *Id.* Plaintiff has shown that several million of Defendant's products were  
19 sold in California alone during the relevant time. Defendant does not dispute that  
20 this is sufficient to meet the numerosity requirement, and the Court finds that this  
21 requirement is met.

22           Defendant claims, however, that the putative class members are not  
23 "ascertainable." It makes four arguments. First, Defendant argues that Plaintiffs'  
24 proposed "class definitions embrace many consumers who do not have valid  
25 claims" in that some putative members have no standing because they suffered no  
26 injury, and would therefore have to be individually screened out of the class. (Doc.  
27 no. 170-1 (opp'n) at 56.) To the extent the argument is directed at the class  
28

1 definition, it was rejected in *Briseno v. ConAgra Foods, Inc.*, 844 F.3d 1121 (9th  
2 Cir. 2017). At class certification stage, it is sufficient that the class be defined by  
3 an objective criterion, *i.e.*, whether the class members purchased the relevant  
4 products. *See id.* at 1124 (affirming decision to the same effect). This is met here,  
5 because Plaintiffs list the relevant products in the definition of each proposed class.

6 To the extent the argument is directed to standing specifically, it is also  
7 rejected. "In a class action, standing is satisfied if at least one named plaintiff  
8 meets the requirements." *Bates v. United Parcel Serv., Inc.*, 511 F.3d 974, 985  
9 (9th Cir. 2007). Defendant attacked each class representative's standing in its  
10 summary judgment motion. The Court concluded that all class representatives had  
11 standing at least as to some of their claims. (Doc. no. 209 (order) at 4-8.)

12 To the extent Defendant suggests that the class definition is overbroad  
13 because it may potentially contain some members who were not injured, the issue  
14 is better addressed in terms of the predominance requirement under Rule 23(b)(3).  
15 *Briseno*, 844 F.3d at 1125 n.4 (citing *Torres v. Mercer Canyon, Inc.*, 835 F.3d  
16 1125, 1136-39 (9th Cir. 2016)). Moreover, as a practical matter, overinclusiveness  
17 in class actions involving low-cost consumer goods presents a low risk of  
18 fraudulent or mistaken claims, "perhaps to the point of being negligible" because  
19 they generate "consistently low participation rates," which makes it "very unlikely  
20 that non-deserving claimants would diminish the recovery of participating, bona  
21 fide class members." *Id.* at 1130 (internal quotation marks, citation and footnote  
22 omitted).

23 Second, Defendant contends that "Plaintiffs' class definitions are unworkable  
24 because the members cannot be reliably identified," as "[m]ost customers do not  
25 remember the specific types of products they bought or when they purchased  
26 them." (Doc. no. 170-1 at 57.) Defendant concedes that this argument was  
27 rejected in *Briseno* (*id.* at 58 n.51), which held that Rule 23 does not require the  
28

1 class representative to prove an "administratively feasible" way to identify each  
2 putative class member. 844 F.3d at 1128-29. "[N]either Rule 23 nor the Due  
3 Process Clause requires actual notice to each individual class member," but allow  
4 for "notice by publication . . . , or even at an appropriate physical location," *id.* at  
5 1128-29, to the members who cannot "be identified through *reasonable* effort,"  
6 Fed. R. Civ. Proc. 23(c)(2)(B) (emphasis added).

7 Third, Defendant maintains that the class settlement in *Delacruz v.*  
8 *CytoSport*, U.S. Distr. Ct. N.D. Cal. case no. 11cv3532, "released any claims based  
9 on the protein present in Muscle Milk shakes sold between July 18, 2007 and  
10 December 31, 2012." (Doc. no. 170-1 at 57.) The settlement agreement and the  
11 order granting final approval of settlement each include a broad release clause,  
12 which apparently intended to preclude claims such as the claims asserted in this  
13 action. (*See Delacruz*, doc. no. 67-1 (first am. settlement agreement) at 6-7 & 16-  
14 17; doc. no. 91 (order) at 13-15.) However, a class action settlement's "bare  
15 assertion that a party will not be liable for a broad swath of potential claims does  
16 not necessarily make it so." *Hesse v. Spring Corp.*, 598 F.3d 581, 590 (9th Cir.  
17 2010).

18 A settlement agreement may preclude a party from bringing a related  
19 claim in the future even though the claim was not presented and might  
20 not have been presentable in the class action, but only where the  
21 released claim is based on the identical factual predicate as that  
underlying the claims in the settled class action.

22 *Id.* (internal quotation marks and citations omitted). The claims asserted in this  
23 action are not based on the "identical factual predicate" as *Delacruz*. *Delacruz* was  
24 not directed at any representations made with respect to Defendant's protein  
25 powders, and to the extent it was directed at the liquid shakes, it did not attack  
26 representations regarding the quantity of protein. (*See Delacruz*, doc. no. 185-14

27 /////  
28

1 (second am. compl.); doc. no. 67-1 at 2, 11-12; doc. no. 91 at 4, 7-8.) Accordingly,  
2 *Delacruz* does not limit the scope of the class proposed in this action.

3 Fourth, Defendant argues that the label for Monster Milk: Lean Muscle  
4 Protein Supplement, a protein powder, was changed during the proposed class  
5 period to exclude the reference to "Lean Lipids." Defendant argues that  
6 individuals who purchased this product after the label change "cannot be included  
7 in any class." (Doc. no. 170-1 at 57.) Although Defendant is correct that the  
8 reference to "Lean Lipids" was removed, other allegedly misleading references to  
9 "lean" remained. (Doc. no. 157-22 (Kashima Decl. App'x A); *cf id.* at 2-15  
10 (referencing "Lean Lipids") & *id.* at 16-17 (no longer referencing "Lean Lipids,"  
11 but including the claims "new leaner formula," "lean protein," and "lean muscle  
12 protein supplement".) Accordingly, the removal of "Lean Lipids" from some of  
13 the labels has no effect on class certification in this action.

14 **2. Commonality Under Rule 23(a) and Predominance Under**  
15 **Rule 23(b)(3)**

16 The second element of Rule 23(a) requires the existence of "questions of law  
17 or fact common to the class." Fed. R. Civ. P. 23(a)(2). To meet this requirement,  
18 the putative class members' claims must depend on a common contention, which  
19 must be of such nature that it is capable of class-wide resolution. Decision on the  
20 contention must

21 resolve an issue that is central to the validity of each one of the claims  
22 in one stroke. [¶] What matters to class certification is not the raising  
23 of common "questions" . . . but, rather the capacity of a classwide  
24 proceeding to generate common *answers* apt to drive the resolution of  
25 the litigation. Dissimilarities within the proposed class are what have  
the potential to impede the generation of common answers.

26 *Dukes*, 564 U.S. at 350 (internal quotation marks and citation omitted).

27 //



1 Similarly, the predominance inquiry under Rule 23(b)(3) "tests whether  
2 proposed classes are sufficiently cohesive to warrant adjudication by  
3 representation." *Amchem Prods, Inc. v. Windsor*, 521 U.S. 591, 623 (1997).  
4 Unlike Rule 23(a)(2), which is met when there is "even a single common  
5 question," *Dukes*, 564 U.S. at 359 (quotation marks and brackets omitted), Rule  
6 23(b)(3) requires that "common questions *predominate* over any questions  
7 affecting only individual class members." *Amgen*, 568 U.S. at 469 (internal  
8 quotation marks and citation omitted, emphasis in original).

9 Because "Rule 23(a)(2)'s 'commonality' requirement is subsumed under, or  
10 superseded by, the more stringent Rule 23(b)(3) requirement that questions  
11 common to the class 'predominate over' other questions[.]" *Amchem*, 521 U.S. at  
12 609, *see also id.* at 623, the Court considers these requirements – commonality and  
13 predominance – together. The predominance inquiry begins "with the elements of  
14 the underlying cause of action." *Erica P. John Fund, Inc. v. Halliburton Co.*, 563  
15 U.S. 804, 809 (2011).

16 Defendant argues that certification should be denied because the alleged  
17 claims are "idiosyncratic individual claims." (Doc. no. 170-1 at 37.) With respect  
18 to the protein powder products, "no one cared about" the L-glutamine and "lean"  
19 representations, and each consumer purchased the products for his or her own  
20 individual reasons. (*Id.*) With respect to the protein shake products, according to  
21 Defendant, Plaintiffs cannot prove a "common shortfall" for the protein content  
22 statement, because any such shortfall differs among the various protein shake  
23 formulations. For all products Defendant attacks Plaintiffs' proposed method of  
24 calculating damages on a class-wide basis. (*Id.* at 50.) Finally, Defendant argues  
25 that a nationwide class cannot be certified because of individual choice of law  
26 questions. (*Id.* at 35-37.) These arguments are addressed below.

27 /////  
28

1 a. Warranty Claims

2 Plaintiff seeks certification of the MMWA claim for the California, Florida  
3 and Michigan subclasses. (Doc. no. 157 at 2-3.) This claim was dismissed in the  
4 order granting in part Defendant's summary judgment motion. (Doc. no. 209 at 10-  
5 12.) Accordingly, the request to certify the MMWA claim is denied as moot.

6 Plaintiffs' intent with respect to the state law claims for breach of express  
7 warranty is unclear. In the notice of motion, Plaintiffs state that if their MMWA  
8 claim is not certified, they seek to certify the state law warranty claims. (Doc. no.  
9 157 at 3 n.2.) However, Plaintiffs do not brief certification of these state law  
10 claims, although they refer to them in two footnotes. (Doc. no. 157-1 at 32-33 n.  
11 14 & 15.) They also state that they "only move for certification of their MMWA  
12 claims at this time." (*Id.* at 34 n.16.) Their intent regarding certification of the  
13 state law breach of express warranty claims is therefore unclear.

14 To the extent Plaintiffs may have intended to certify these claims, the issue  
15 is moot as to the Florida and Michigan claims, which were dismissed at summary  
16 judgment. (*See* doc. no. 209 at 8-10.) As to the California claim, Plaintiffs do not  
17 meet their burden.

18 Defendant argues that Plaintiffs cannot meet the predominance requirement  
19 because breach of express warranty requires individual proof of reliance and  
20 causation. On summary judgment, the Court determined that California law does  
21 not require proof of reliance. (Doc. no. 209 at 10 (citing Jud. Council of Cal. Civ.  
22 Jury Instr. ("CACI") no. 1230 cmt (2017) (quoting *Hauter v. Zogarts*, 14 Cal.3d  
23 104, 115 (1975)); Cal. Comm. Code § 2313(1) & Cal. Code Cmt. 2).) However, it  
24 requires proof of causation. CACI no. 1230 ¶6 ("That the failure of the [product]  
25 to be as represented was a substantial factor in causing [plaintiff]'s harm.").  
26 Plaintiffs do not address causation for this cause of action. (*See* docs. no. 157-1,  
27 185.) Accordingly, to the extent Plaintiffs request that the California subclass  
28

1 include a claim for breach of express warranty, their motion is denied for failure to  
2 properly support it.

3 b. California Consumer Protection Claims

4 i. *Elements*

5 Plaintiffs allege false or misleading statements on Defendant's product labels  
6 in violation of the UCL,<sup>3</sup> FAL<sup>4</sup> and CLRA, Cal. Civ. Code § 1770(a)(5).<sup>5</sup>

7 The standard for determining whether a defendant misrepresented the  
8 characteristics, uses or benefits of goods and services under Civil  
9 Code section 1770, subdivision (a)(5) is the same as that for  
10 determining whether there was false advertising under the UCL and  
11 false advertising law.

12 <sup>3</sup> The UCL provides in pertinent part:

13 unfair competition shall mean and include any unlawful, unfair or  
14 fraudulent business act or practice and unfair, deceptive, untrue or  
15 misleading advertising and any act prohibited by Chapter 1  
(commencing with Section 17500) of Part 3 of Division 7 of the  
16 Business and Professions Code.

17 Cal. Bus. & Prof. Code § 17200.

18 <sup>4</sup> The FAL provides in pertinent part:

19 It is unlawful . . . to make or disseminate . . . in any . . . advertising . . .  
20 or in any other manner or means whatever . . . any statement,  
21 concerning . . . personal property . . ., which is untrue or misleading,  
22 and which is known, or which by the exercise of reasonable care  
23 should be known, to be untrue or misleading . . .

24 Cal. Bus. & Prof. Code § 17500.

25 <sup>5</sup> The pertinent CLRA provision reads,

26 The following unfair methods of competition and unfair or deceptive  
27 acts or practices undertaken by any person in a transaction intended to  
28 result or that results in the sale or lease of goods or services to any  
consumer are unlawful: . . .

(5) Representing that goods or services have sponsorship, approval,  
characteristics, ingredients, uses, benefits, or quantities that they do  
not have or that a person has a sponsorship, approval, status,  
affiliation, or connection that he or she does not have.

Cal. Civ. Code § 1770(a)(5).

1 *Chapman v. Skype, Inc.*, 220 Cal. App. 4th 217, 230 (2013); *see also Williams v.*  
2 *Gerber Prods Co.*, 553 F.3d 934, 938 (9th Cir. 2008) (am. Dec. 22, 2008). In this  
3 regard, "it is necessary only to show that members of the public are likely to be  
4 deceived." *Tobacco II Cases*, 46 Cal.4th 298, 312 (2009) (internal quotation  
5 marks, brackets, ellipsis and citation omitted). The "focus is on the defendant's  
6 conduct, rather than the plaintiff's damages, in service of the statute's larger  
7 purpose of protecting the general public against unscrupulous business practices."  
8 *Id.* at 312; *see also id.* at 324. Accordingly, no individualized proof is required to  
9 show deceptiveness.

10 In class actions alleging UCL and FAL violations, once a class  
11 representative establishes statutory standing,<sup>6</sup> injunctive relief and restitution are  
12 "available without individualized proof of deception, reliance and injury."  
13 *Tobacco II Cases*, 46 Cal.4th at 319-20.

14 The CLRA claim requires the additional "showing of actual injury as to each  
15 class member." *Steroid Hormone Prod. Cases*, 181 Cal. App. 4th 145, 155 (2010);  
16 *see also id.* at 156 (discussing Cal. Civ. Code § 1780(a) ("Any consumer who  
17 suffers any damage as a result of the use . . . of a . . . practice declared to be  
18 unlawful by Section 1770 may bring an action . . .")). However, injury, as well as  
19 reliance and causation, can be proved "by showing that the alleged misleading  
20 statement was material, even if [Defendant] might be able to show that some class  
21 members would have bought the products even if they had known [the  
22 representation was false]." *Steroid Prod. Cases*, 181 Cal. App. 4th at 156-57.  
23 "Materiality of the alleged misrepresentation generally is judged by a 'reasonable  
24 man' standard. In other words, a misrepresentation is deemed material if a

25 \_\_\_\_\_  
26 <sup>6</sup> Defendant's contention on summary judgment that Plaintiffs could not  
27 establish statutory standing because they did not rely on Defendant's  
28 representations was granted in part and denied in part. (Doc. no. 209 at 5-8.)  
Nevertheless, there remains a named Plaintiff with statutory standing for each  
consumer protection claim as to each allegedly misleading statement. (*Id.*)

1 reasonable man would attach importance to its existence in determining his choice  
2 of action in the transaction in question . . ." *Id.* at 157 (internal quotation marks,  
3 brackets and citation omitted).

4 *ii. Class Member Reliance and Causation --*  
5 *L-glutamine and "Lean" Statements on Protein*  
6 *Powder Labels; Daubert Motion*

7 Defendant argues certification should be denied because Plaintiffs presented  
8 no proof that the L-glutamine and "lean" statements were deceptive. (Doc. no.  
9 170-1 at 42, 45.) As discussed above, for all three California consumer protection  
10 claims, the issue is decided on a class-wide basis, regardless of each individual  
11 consumer's understanding. *See Tobacco II Cases*, 46 Cal.4th at 312 ("it is  
12 necessary only to show that members of the public are likely to be deceived"); *see*  
13 *also Chapman*, 220 Cal. App. 4th at 230 (same standard applies to UCL, FAL and  
14 CLRA claims); *Williams*, 553 F.3d at 938 (same). Moreover, it is not necessary to  
15 prove actual falsity, it is sufficient to prove that the representation, "although true,  
16 is either actually misleading or . . . has a capacity, likelihood or tendency to  
17 deceive or confuse the public." *Chapman*, 220 Cal. App. 4th at 226 (internal  
18 quotation marks and citations omitted); *see also Tobacco II Cases*, 46 Cal.4th at  
19 312. Whether Plaintiffs are successful in proving deceptiveness or not, the  
20 outcome of this issue affects the claims on a class-wide basis. The merits of this  
21 issue therefore do not preclude class certification. Accordingly, it is neither  
22 necessary nor appropriate for the Court to decide it at this stage. *See Amgen*, 568  
23 U.S at 466.

24 Defendant next maintains that individual "proof of causation and thereby  
25 reliance" is required. (Doc. no. 170-1 at 39.) The argument is based on the  
26 premise that to avoid individual proof of causation, Plaintiffs must show that the  
27 "lean" and L-glutamine representations were material to the class members. This  
28

1 is not required for the UCL and FAL claims, but is required for the CLRA claim.  
2 *See Steroid Prod. Cases*, 181 Cal. App. 4th at 156-57.

3 In support of their contention that the L-glutamine and "lean"  
4 representations are material, Plaintiffs primarily rely on their marketing expert  
5 Elizabeth Howlett, Ph.D. (Doc. no. 157-8 ("Howlett Report") at 8.) Defendant  
6 moves to exclude Dr. Howlett's opinions as inadmissible under Rule 702 of the  
7 Federal Rules of Evidence. (Doc. no. 170-1 at 59.) For the reasons stated below,  
8 Defendant's *Daubert* motion is granted in part.

9 The party offering evidence bears the burden of showing that the evidence is  
10 admissible. *See Bourjaily v. United States*, 483 U.S. 171, 175-76 (1987).  
11 Accordingly, Plaintiffs bear the burden of showing that Dr. Howlett's materiality  
12 opinions are admissible. To be admissible, among other things, expert opinion  
13 must be based on sufficient facts or data. Fed. R. Evid. 702(b).

14 Dr. Howlett based her opinion on two factors -- role of L-glutamine in  
15 muscle recovery and immune system function, and Defendant's own marketing  
16 research. (Howlett Report at 8; *see* Videotaped Deposition of Dr. Elizabeth  
17 Howlett ("Howlett Depo.") at 30-35; *see also id.* at 21.)<sup>7</sup> Dr. Howlett did not cite  
18 any references for her opinions regarding the function of L-glutamine in the body,  
19 but relied on "common knowledge." (Howlett Depo. at 31-34; *see also* Howlett  
20 Report at 8.) However, she admitted that the effect of L-glutamine on the body  
21 was "out of [her] area of expertise." (Howlett Depo. at 37.) She also admitted that  
22 Defendant's marketing research materials referenced in her report were not  
23 referencing L-glutamine, but were more generally addressing protein content. (*Id.*  
24 at 32-35.)

25 //

26 \_\_\_\_\_  
27 <sup>7</sup> Excerpts from the Howlett Depo. were filed as doc. no. 170-4 (Kaplan Decl.  
28 Ex. F) and doc. no. 185-7 (Marino Decl. Ex. E). Throughout this Order, page  
references to deposition testimony are to the page numbers in the transcript.

1 Plaintiffs point to Dr. Howlett's deposition testimony that the primary source  
2 of the information she reviewed for her report was Defendant's own marketing  
3 research. (Doc. no. 185 at 26 (citing Howlett Depo. at 21).) The problem with this  
4 argument is that Dr. Howlett's report cites to only a few pages out of those  
5 documents (Howlett Report at 8), which do not address L-glutamine. (Howlett  
6 Depo. at 32-35). Based on the foregoing, Dr. Howlett's opinion that L-glutamine  
7 representations were material to the consumers is unsupported by sufficient facts or  
8 data. Defendant's motion to exclude this opinion is granted for purposes of the  
9 pending motion for class certification.

10 In addition to moving to exclude Dr. Howlett's opinions, Defendant offered  
11 the opinion of its marketing expert Ravi Dhar to argue that the L-glutamine  
12 representations were not material. (Doc. no. 170-1 at 43 (citing doc. no. 170-7  
13 ("Dhar Report").) Dr. Dhar opined, based on a consumer survey he conducted, that  
14 "the overwhelming majority of the respondents do not even mention L-glutamine  
15 as a reason for buying the products." (Dhar Report at 10; *see also id.* at 10-13.)

16 Plaintiffs do not address Dr. Dhar's opinion. Instead, they offer evidence of  
17 their own independently of Dr. Howlett's opinion. They rely on, among other  
18 things, the deposition testimony of Adam Schrententhaler, Defendant's Director of  
19 Product Development (Transcript of the Testimony of Adam Schrententhaler  
20 ("Schrententhaler Depo.")),<sup>8</sup> and Defendant's own marketing research (doc. no.  
21 170-38 through 40 (Kashima Decl. Exs. M-O)). (*See* doc. no. 185 at 19-20, 37.)

22 Adam Schrententhaler and his team formulated all Defendant's products,  
23 "created all the label content, [and] produced claim substantiation."  
24 (Schrententhaler Depo. at 13.) He testified it was Defendant's understanding that  
25 L-glutamine played a role for athletes in muscle maintenance or building. (*Id.* at  
26

27 <sup>8</sup> Excerpts from the Schrententhaler Depo. were filed as doc. no. 157-26 and  
28 157-32 (Kashima Decl. Exs. A & G).

1 124.) Defendant's marketing research shows that muscle maintenance and building  
2 were important to consumers who purchased protein supplements. (*See, e.g.*, Ex.  
3 N at 034911; Ex. O at 034303.)<sup>9</sup> L-glutamine content was specified, and its  
4 function for athletes was highlighted, on some of Defendant's protein powder  
5 labels. (Kashima Decl. Ex. K at 29-36 ("5g L-glutamine to enhance muscle tissue  
6 recovery/repair").) This evidence tends to show, independent of Dr. Howlett's  
7 opinions, that L-glutamine representations were material.

8 Plaintiffs contend that their evidence is sufficient to prevail on the  
9 predominance issue with respect to the L-glutamine representations. (Doc. no. 185  
10 at 20.) They argue that materiality is a merits issue that should not be decided at  
11 the class certification stage. (*Id.* at 18.) According to Plaintiffs, the relevant  
12 inquiry is whether materiality can be proven on a class-wide basis and not whether  
13 the alleged misrepresentations were in fact material. (*Id.* at 20.) Citing *Clemens v.*  
14 *DaimlerChrysler Corp.*, 534 F.3d 1017, 1026 (9th Cir. 2008), Plaintiffs allow that  
15 "to the extent [they] must show some *prima facie* showing of materiality at class  
16 certification, '[s]urveys and expert testimony regarding consumer assumptions and  
17 expectations may be offered but are not required; anecdotal evidence may suffice."  
18 (Doc. no. 185 at 19 (emphasis in original) (quoting *Clemens*, 534 F.3d at 1026).)

19 *Clemens* did not address class certification. It held that to prevail on the  
20 issue of materiality at summary judgment, evidence of consumer assumptions and  
21 expectations may be sufficient to raise a genuine issue of fact. 534 F.3d at 1026.<sup>10</sup>  
22 Unlike summary judgment, prevailing on a motion for class certification requires  
23 the court to resolve any factual disputes necessary to determine whether class  
24 certification requirements are met. *Ellis v. Costco Wholesale Corp.*, 657 F.3d 970,  
25 983 (9th Cir. 2011). In *Ellis*, the district court decision was vacated because the

26 \_\_\_\_\_  
27 <sup>9</sup> Page references are to the page numbers assigned by the parties in discovery.

28 <sup>10</sup> The plaintiff's showing in *Clemens* did not suffice, however, and summary  
judgment was granted for the defendant. *Id.*



1 court did not resolve the factual dispute, presented through conflicting expert  
2 opinions, whether there was a nationwide common pattern and practice of alleged  
3 employment discrimination that could affect the class as a whole. This was  
4 required before the court could decide whether there was commonality of issues of  
5 fact or law for purposes of class certification. *Id.* at 98-84. *Ellis* expressly rejected  
6 the reasoning, relied upon by Plaintiffs here, that because both sides presented  
7 admissible evidence, a finding of commonality was appropriate. *Id.* at 984.

8 Materiality of the alleged misrepresentations is central to finding  
9 commonality and predominance, and therefore to class certification of the CLRA  
10 claim. If the alleged misrepresentations are material, individualized proof of  
11 reliance and causation is not required, and can be presumed on a class-wide basis.  
12 *Steroid Prod. Cases*, 181 Cal. App. 4th at 156-57. If they are not material, the  
13 claim does not necessarily fail, but individual proof of reliance and causation will  
14 be required for each would-be class member, thus precluding class certification.

15 Both parties presented admissible evidence tending to show that the L-  
16 glutamine representations were or were not material. *Ellis* requires the Court to  
17 resolve the factual dispute. Plaintiffs bear the burden to show that all requirements  
18 for class certification are met. This includes a showing of materiality. *See*  
19 *Comcast*, 569 U.S. at 33.

20 Plaintiffs do not address Dr. Dhar's opinion, but merely dismiss it as "some  
21 conflicting evidence" and argue that "Defendant's self-serving, post-dispute expert  
22 reports do not foreclose certification of the proposed Class." (Doc. no. 185 at 20.)  
23 Given admissible evidence on both sides of the materiality issue, which appears to  
24 be evenly balanced, Plaintiffs' arguments are insufficient to carry their burden of  
25 showing that the L-glutamine representations were material.

26 The parties also dispute whether Defendant's "lean" representations on the  
27 protein powder labels were material. Plaintiffs rely on Dr. Howlett's opinion that  
28

1 "fat level of Lean Muscle Milk Products is material." (Howlett Report at 8; *see*  
2 *also* Howlett Depo. at 37, 42-43.) In this regard, Dr. Howlett's opinion was  
3 focused on the "Lean Lipids" representation on the product labels. (Howlett Depo.  
4 at 42-43, 79.) She based her materiality opinion on Defendant's marketing  
5 research which stated that weight loss management was important to consumers.  
6 (Howlett Report at 8 (citing Ex. O at 34303); Howlett Depo. at 38, 42-43.)

7 Defendant criticizes this basis because the document considered by Dr.  
8 Howlett does not reference "Lean Lipids" and addresses a whole category of  
9 protein products on the market, not only Muscle Milk products. (Doc. no. 170-1 at  
10 46.) This argument is rejected. Defendant's research concluded that weight loss  
11 management was important to consumers. (*See, e.g.*, Ex. O at 34303.) It is  
12 therefore not a stretch to opine that consumers find fat content representations  
13 material. It is undisputed that "Lean Lipids" refers to the fat in Defendant's  
14 product. Defendant's motion to exclude Dr. Howlett's materiality opinion  
15 regarding "Lean Lipids" representation is denied.

16 In addition to attacking the admissibility of Dr. Howlett's opinion, Defendant  
17 relies on Dr. Dhar's report. (Doc. no. 170-1 at 46.) Based on a consumer survey,  
18 Dr. Dhar opined that the "lean" statements on the labels did not have an impact on  
19 the purchase decision. (Dhar Report at 15-17.)

20 In response, in addition to Dr. Howlett's report, Plaintiffs point to  
21 Defendant's marketing research showing that a significant portions of consumers  
22 purchase protein powder for weight loss and weight management. (*See, e.g.*, Ex.  
23 M. at 34847-48; Ex. N. at 34911.) They do not address Dr. Dhar's report, however,  
24 other than to dismiss it in a summary fashion outlined in the context of L-  
25 glutamine representations above. As noted, where both sides have come forward  
26 with admissible evidence of materiality, which appears to be evenly balanced, this

27 /////

28

1 is insufficient for Plaintiffs to meet their burden of showing, for purposes of class  
2 certification, that the "lean" representations were material.

3 For the foregoing reasons, Defendant's motion to exclude Dr. Howlett's  
4 opinion is granted insofar as she opined that the L-glutamine representations were  
5 material. This opinion is excluded for purposes of the pending class certification  
6 motion only. Defendant's *Daubert* motion is denied in all other respects. Plaintiffs  
7 failed to meet their burden, with respect to the CLRA claim only, that the L-  
8 glutamine and "lean" representations were material, and that causation can be  
9 proved on a class-wide basis. This precludes certification of the CLRA claim to  
10 the extent it is based on L-glutamine and "lean" statements on protein powder  
11 labels.

12 *iii. Class Member Injury -- Protein Content*  
13 *Statements on Protein Shake Labels*

14 With respect to the protein shakes, Defendant argues that Plaintiffs cannot  
15 meet the predominance requirement because they "failed to offer any common  
16 evidence of injury," and because the parties would have to test each batch and  
17 bottle of the many formulations of protein shakes. (Doc. no. 170-1 at 49.)  
18 Individual proof of injury is not required for the class members to prevail on the  
19 UCL and FAL claims; however, it is required for the CLRA claim. *Steroid Prod.*  
20 *Cases*, 181 Cal. App. 4th at 155.

21 Defendant also argues that Plaintiffs used invalid methodology to test the  
22 protein content of the shakes. (Doc. no. 170-1 at 48-49.) Alternatively, it argues  
23 that protein content was not uniformly overstated, because in some instances it was  
24 accurately stated and in others it was actually greater than stated. (*Id.* at 49.)  
25 These arguments go to the issue whether Plaintiffs can prove deceptiveness of the  
26 protein content statement. As previously discussed, regardless of Plaintiffs'

27 /////  
28

1 success or failure on this issue, the result applies to the class as a whole.<sup>11</sup> *See*  
2 *Tobacco II Cases*, 46 Cal.4th at 312 ("members of the public are likely to be  
3 deceived"); *see also Chapman*, 220 Cal. App. 4th at 226 (not necessary to prove  
4 actual falsity). As the issue does not preclude class certification, it need not, and  
5 should not, be decided at this stage. *See Amgen*, 568 U.S at 466.

6 Defendant next contends that the claim should not be certified because  
7 Defendant offered many varieties of the protein shakes during the class period, and  
8 each variety had its own stated protein content and alleged shortfall. (Doc. no.  
9 170-1 at 47-49.) Defendant maintains that this shows there is no "common  
10 shortfall" for all protein shake varieties. (*Id.* at 48.) Accepting at face value the  
11 contention that the discrepancy varies among the various shake formulations, and  
12 considering that the standard is whether "members of the public are likely to be  
13 deceived," *Tobacco II Cases*, 46 Cal.4th at 312, it is not fatal to class certification  
14 if the shortfall is not the same for each variety.

15 Although different products may have to be tested for protein content,  
16 Defendant's argument that each batch and bottle of each variety of the shake will  
17 have to be tested to determine whether the class members were injured (doc. no.  
18 170-1 at 49) is rejected. The parties stipulated for purposes of class certification  
19 that the amount of protein did not vary materially between different batches of the  
20 same product during the class period. (Doc. no. 104 at 1.) Further, Elizabeth  
21 Kimball, Defendant's nutritional scientist and compliance manager (Deposition of  
22 Elizabeth Willard Kimball, Ph.D. ("Kimball Depo.") at 45-46),<sup>12</sup> admitted that  
23 there were no variations with respect to the base product formula between various  
24 flavors of the same product. (*See Kimball Depo.* at 45-46, 48-52.)

25 \_\_\_\_\_  
26 <sup>11</sup> Defendant acknowledges this is a merits issue. (Doc. no. 170-1 at 49  
("Plaintiffs' claims fail on the merits."))

27 <sup>12</sup> Excerpts from the Kimball Depo. were filed as doc. no. 157-33 (Kashima  
28 Decl. Ex. H.)

1 As Defendant itself suggests, a proper sampling method is sufficient to  
2 determine whether the actual protein content varies from the statements on the  
3 labels. (*See* doc. no. 170-1 at 49 n.38.) There is no dispute whether the alleged  
4 shortfall can be proved or disproved by sampling, but only as to the validity of the  
5 chosen sampling method. Methodology is relevant to the sufficiency, and  
6 potentially admissibility, of the evidence to prove deceptiveness, and need not be  
7 resolved for purposes of class certification. Defendant's argument that certification  
8 should be denied because Plaintiffs would have to make an individualized showing  
9 of protein content is rejected.

10 *iv. Calculation of Damages*

11 Defendant next contends that class certification should be denied based on  
12 *Comcast v. Behrend*, 569 U.S. 27 (2013), which held that "the plaintiffs must be  
13 able to show that their damages stemmed from the defendant's actions that created  
14 the legal liability." *Leyva v. Medline Indus. Inc.*, 716 F.3d 510, 514 (9th Cir.  
15 2013)(citing *Comcast*, 569 U.S. at 37-38). In *Comcast* the plaintiffs advanced four  
16 theories of antitrust liability, only one of which was approved for class treatment.  
17 *Comcast*, 569 U.S. at 35. The plaintiffs' proposed damage calculation would  
18 include damages caused by all four theories of liability combined. *Id.* at 36. The  
19 holding of *Comcast* is based on the "unremarkable premise" that if the plaintiffs  
20 prevailed, they would be entitled only to damages resulting from one theory of  
21 liability. *Id.* at 35. The Court concluded,

22 It follows that a model purporting to serve as evidence of damages in  
23 this class action must measure only those damages attributable to that  
24 theory. If the model does not even attempt to do that, it cannot  
25 possibly establish that damages are susceptible to measurement across  
the entire class for purposes of Rule 23(b)(3).

26 *Id.*

27 // // // //

1 Plaintiffs seek restitution. (Doc. no. 157-1 at 28.) "The difference between  
2 what the plaintiff paid and the value of what the plaintiff received is a proper  
3 measure of restitution." *In re Vioxx Class Cases*, 180 Cal. App. 4th 116, 131  
4 (2009). Plaintiffs propose two alternative models of calculating damages  
5 stemming specifically from Defendant's protein, L-glutamine and "lean"  
6 representations. To the extent these models attribute damages to each alleged  
7 misrepresentation separately, they comply with *Comcast*.

8 Defendant also argues that class certification should be denied because  
9 neither of the proposed damages models has been performed. Defendant cites no  
10 binding authority holding that class certification should be denied unless the  
11 experts have already calculated damages,<sup>13</sup> especially when, as here, the parties  
12 bifurcated class certification and merits discovery. (Doc. no. 170-4 (Kaplan Decl.  
13 Ex. H (Joint Rule 26(f) Report and Discovery Plan)) at 78.) Plaintiffs filed expert  
14 declarations explaining their proposed models.

15 Plaintiffs propose conjoint analysis to calculate class-wide damages  
16 attributable to protein content statements on the protein shake labels, and L-  
17 glutamine and "lean" statements on the protein powder labels.<sup>14</sup> Conjoint analysis  
18 is a quantitative consumer preference analysis used to measure the relative value of  
19 various product attributes. (Doc. no. 157-8 ("Howlett Report") at 9.) It has been  
20 used in marketing research since the 1970s. (*Id.* at 10.) Dr. Howlett opined that it  
21 is possible "to use the conjoint analysis to quantify the Price Premium associated  
22 with the allegedly false 'Protein, L-Glutamine, and Lean Claims' on a class-wide  
23 basis." (*Id.* at 6.)

---

24  
25 <sup>13</sup> This issue was not an impediment to class certification in *In re Conagra*  
26 *Foods*, which considered at length proposed expert opinions regarding class-wide  
proof of damages. 90 F. Supp. 3d 945, 1025-32. 945 (C.D. Cal. 2015); *aff'd*  
*Briseno v. ConAgra Foods, Inc.*, 844 F.3d 1121 (9th Cir. 2017).

27 <sup>14</sup> Although class certification was denied for the CLRA claim based on the L-  
28 glutamine and "lean" statements, damages analysis is relevant to the UCL and FAL  
claims based on the same statements.

1 Dr. Howlett proposes to use the choice-based variant of the conjoint  
2 analysis. (*Id.* at 11.) In a choice-based conjoint analysis, the study respondents are  
3 presented with a product that has multiple options for each studied attribute, such  
4 as a specific number of car color options and whether the car has a sunroof. (*Id.* at  
5 9.) The choices presented to the respondents have all combinations of the studied  
6 attributes. By analyzing the respondents' choices, it is possible to quantify the  
7 relative impact of each attribute on product preference, *i.e.*, the value of each  
8 attribute. (*Id.*) With statistical analysis, it is possible to derive the distribution of  
9 preferences across all respondents. (*Id.* at 11.) If one of the studied attributes is  
10 price or premium over average market price, the analysis can determine the dollar  
11 value of each attribute or the percentage of the average market price associated  
12 with each attribute. (*Id.* at 9, 12.)

13 For the pending case, Dr. Howlett proposes to use a national online survey  
14 directed to a sample of consumers who purchased one or more of relevant protein  
15 shake or powder products. (*Id.* at 12.) Defendant's shake products are to be used  
16 to study the importance of the protein amount, and the protein powder products to  
17 study L-glutamine and "lean" representations. (*Id.* at 13.) The study would ensure  
18 that the product attributes of the highest importance to the sampled consumers are  
19 included. (*Id.*) The responses will be statistically analyzed to determine the value  
20 of each of the three attributes, for example an additional gram of protein, presence  
21 or absence of L-glutamine and presence or absence of "Lean Lipids" statements.  
22 (*Id.* at 14-15.) The value of each additional increment of protein or presence of L-  
23 glutamine or "Lean Lipids" will be separately multiplied by total product purchases  
24 to arrive at class-wide damages. (*Id.* at 16.)

25 Defendant criticizes Dr. Howlett's proposed study by arguing that she  
26 "assumes the ultimate conclusion that consumers cared about and paid a price  
27 premium for the L-glutamine or Lean Lipids statements," because she intends to  
28

1 include them in the conjoint analysis. (Doc. no. 170-1 at 55.) These attributes  
2 must be included, because they are the attributes studied by her analysis. Dr.  
3 Howlett testified that if consumers are indifferent to these attributes, the result of  
4 the analysis would show it. (See Howlett Depo. at 51-53.) Defendant's argument  
5 omits the pertinent part of Dr. Howlett's testimony. (See doc. no. 170-1 at 55  
6 (citing Howlett Depo. at 51:24-52:14).)

7 Defendant further contends Dr. Howlett "does not know if she could obtain  
8 pricing data she needs." (Doc. no. 170-1 at 56.) Defendant misconstrues Dr.  
9 Howlett's deposition testimony about pricing data. (See doc. no. 170-1 at 56  
10 (citing Harris Depo. at 57-58).) She testified she would use data from market  
11 research firms such as Information Resources, Inc. and Nielsen, which "almost  
12 certainly" is available. (Howlett Depo. at 57-58.) Nowhere in the cited deposition  
13 testimony did Dr. Howlett indicate she could not obtain the pricing data.  
14 Furthermore, Defendants produced their sales data for each product relevant to this  
15 action by state and date. (Doc. no. 157-1 at 41 n.25.)

16 Finally, Defendant argues that Dr. Howlett's analysis does not meet the  
17 *Comcast* requirement that damages be tied only to the liability theory at issue for  
18 class treatment. Plaintiffs' L-glutamine claim is based on the contention that the  
19 protein powder products did not contain any appreciable amount of unbonded L-  
20 glutamine, as opposed to bonded L-glutamine. Defendant contends Dr. Howlett  
21 does not explain how she will determine the value of the unbonded, as opposed to  
22 bonded, L-glutamine. (Doc. no. 170-1 at 55.) Plaintiffs' do not address this  
23 argument. (See doc. no. 185 at 26, 29-31.) Because damages must be based on the  
24 specific theory of liability, certification is denied as to the consumer protection  
25 claims based on L-glutamine statements.

26 As an alternative method of calculating damages attributable to protein  
27 content statements on protein shake products, Plaintiffs propose hedonic regression  
28



1 analysis to be conducted by Jeffrey E. Harris, M.D., Ph.D. (*See* doc. no. 157-7  
2 ("Harris Report") at 6.) Because Dr. Howlett's proposed conjoint analysis of the  
3 same statements is sufficient to meet Plaintiffs' burden to show that damages can  
4 be calculated on a class-wide basis, the Court need not address Defendant's  
5 criticisms of the alternative method.

6 For the foregoing reasons, Plaintiffs met the commonality and predominance  
7 requirements for (1) the UCL, FAL and CLRA claims to the extent they are based  
8 on statements of protein content on protein shake labels; and (2) UCL and FAL  
9 claims to the extent they are based on "lean" statements on protein powder labels.

10 d. Florida Consumer Protection Claims

11 Plaintiffs allege that the false or misleading statements on Defendant's  
12 product labels also violated the FDUTPA, Fla. Stat. §§ 501.201 *et seq.* To prevail  
13 on this claim, a plaintiff must show that that "the alleged practice was likely to  
14 deceive a consumer acting reasonably in the same circumstances." *Fla. Offc. of*  
15 *Atty Gen. v. Commerce Comm. Leasing, LLC*, 946 So.2d 1253, 1258 (Fla. D. Ct.  
16 App. 2007) (internal quotation marks and citation omitted.) The plaintiff "need not  
17 show actual reliance on the representation or omission at issue." *Id.* (citation  
18 omitted). Defendant does not disagree. (*See* doc. no. 170-1 at 24.) This standard  
19 is the same as for the UCL and FAL claims. The measure of damages under the  
20 FDUTPA is the difference in the market value of the product as sold and the  
21 product as promised. *Ft. Lauderdale Lincoln Mercury, Inc. v. Corgnati*, 715  
22 So.2d 311, 313-14 (Fla. D. Ct. App. 1998). It is the same measure as restitution  
23 under the UCL and FAL. Accordingly, for the reasons stated in the context of  
24 California consumer protection claims, Plaintiffs meet the commonality and  
25 predominance requirements for a FDUTPA violation based on the protein content  
26 statements on protein shakes and "lean" statements on protein powders.

27 /////  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

e. Michigan Consumer Protection Claims

Plaintiffs allege that Defendant also violated the MCPA, Mich. Comp. Laws § 445.903(1)(c). The statute prohibits "[u]nfair, unconscionable, or deceptive methods, acts, or practices in the conduct of trade or commerce" defined in pertinent part as "representing that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities that they do not have." *Id.* This provision is identical to the CLRA, Cal. Civ. Code § 1770(a)(5). As with California consumer protection claims, members of a class proceeding under the [MCPA] need not individually prove reliance on the alleged misrepresentations. It is sufficient if the class can establish that a reasonable person would have relied on the representations.

*Dix v. Am. Bankers Life Assur. Co.*, 415 N.W.2d 206, 209 (Mich. Supr. Ct. 1987) (footnote omitted). Plaintiffs concede that the analysis under the MCPA should be the same as under the CLRA. (Doc. no. 157-1 at 31 n.12.) The measure of damages under the MCPA is the same as restitution under California consumer protection statutes -- difference in value between the product as promised and product as sold. *See Mayhall v. A.H. Pond Co., Inc.*, 341 N.W.2d 268, 271-72 (Mich. Ct. App. 1983). Accordingly, for the reasons stated in the context of California consumer protection claims, Plaintiffs meet the commonality and predominance requirements for a Michigan subclass asserting an MCPA violation based on the protein content statements on protein shakes.

f. Nationwide Class for FAL and UCL Violations

Finally, Plaintiffs seek certification of a nationwide class for the FAL and UCL claims. Defendant argues that a nationwide class cannot be certified because California law does not apply to out-of-state putative class members, and that each

/////

1 class member's own state law should apply, thus precluding a finding that common  
2 issues predominate for a nationwide class.

3 California state law applies to the conflict-of-law issue presented by  
4 Plaintiffs' motion to certify a nationwide class. *See Mazza v. Am. Honda Motor*  
5 *Co.*, 666 F.3d 581, 589 (9th Cir. 2012).

6 California law[, rather than the law of a foreign state,] may be used on  
7 a classwide basis so long as its application is not [unconstitutionally]  
8 arbitrary or unfair with respect to nonresident class members, and so  
9 long as the interests of other states are not found to outweigh  
California's interest in having its law applied.

10 *Wash. Mut. Bank v. Super. Ct.*, 24 Cal.4th 906, 921 (2001) (citations omitted).

11 "Under California's choice of law rules, the class action proponent bears the  
12 initial burden to show that California has 'significant contact or significant  
13 aggregation of contacts' to the claims of each class member." *Mazza*, 666 F.3d at  
14 589 (quoting *Wash. Mut. Bank*, 24 Cal.4th at 921). "Such a showing is necessary  
15 to ensure that application of California law is constitutional." *Id.* at 589-90 (citing  
16 *Allstate Ins. Co. v. Hague*, 449 U.S. 302, 310–11 (1981)).

17 It is undisputed that Defendant is incorporated and headquartered in  
18 California, its principal place of business is in California, the final decisions  
19 regarding representations made on product labels were made in California, and  
20 many of the products were produced in California. (*Cf.* doc. no. 157-1 (mot.) at  
21 41-42 (citing Kashima Decl. Ex. A (excerpts from depo. of Adam  
22 Schrententhaler)) *with* doc. no. 170-1 (opp'n) at 35-37.) This constitutes sufficient  
23 contacts between the claims of out-of-state putative class members and the state of  
24 California to meet the constitutional requirement. *See, e.g., Mazza*, 666 F.3d at  
25 590 (corporate headquarters, advertising agency and large part of the putative class  
26 in California).

27 //

1 When the class action proponent makes a showing of the requisite contacts,  
2 [g]enerally speaking[,] the forum will apply its own rule of decision  
3 unless a party litigant timely invokes the law of a foreign state. In  
4 such event that party must demonstrate that the latter rule of decision  
5 will further the interest of the foreign state and therefore that it is an  
appropriate one for the forum to apply to the case before it.

6 *Wash. Mut. Bank*, 24 Cal.4th at 919 (internal quotation marks, brackets and  
7 citations omitted). Defendant contends that the UCL and FAL should not apply to  
8 the out-of-state class members, and that their respective state laws should apply  
9 instead. (*See* doc. no. 170-1 at 35-37.) Defendant bears the burden to show that  
10 the "governmental interest approach," *i.e.*, the choice-of-law analysis under  
11 California law, favors foreign law. *See Mazza*, 666 F.3d at 590 ("burden shifts to  
12 the other side to demonstrate that foreign law, rather than California law, should  
13 apply to class claims") (internal quotation marks and citation omitted).

14 Under the first step of the governmental interest approach, the foreign  
15 law proponent must identify the applicable rule of law in each  
16 potentially concerned state and must show it materially differs from  
17 the law of California. The fact that two or more states are involved  
does not in itself indicate there is a conflict of laws problem.

18 *Wash. Mut. Bank*, 24 Cal.4th at 919-20. Defendant filed a chart titled "Material  
19 Differences in State Consumer Protection and Deceptive Trade Practices." (Doc.  
20 no. 170-6 (Decl. of Matthew Kaplan Ex. T).)<sup>15</sup> It contends that some, but not all,  
21 states require reliance or causation, some require intent to induce reliance, some  
22 have a shorter or longer statute of limitations than California, and some states do  
23 not authorize class actions under consumer protection laws. (*Id.* at 2.) Plaintiffs

24 \_\_\_\_\_  
25 <sup>15</sup> Defendant's brief devotes only one sentence to this issue (doc. no. 170-1 at  
26 36) and the entirety of the discussion is presented in a 58-page single spaced chart  
27 in 8-point print. (Doc. no. 170-6 (Decl. of Matthew Kaplan Ex. T).) This is a  
28 brazen run around the page limits, which were already extended by parties' request.  
(*See* doc. no. 154 (Order Regarding Briefing Plaintiffs' Motion for Class  
Certification and Defendant's Summary Judgment and *Daubert* Motions).) Failure  
to comply with orders of the Court is grounds for sanctions. Civ. Loc. Rule 83.1.

1 counter that there is no material difference, because the UCL and FAL are  
2 "additive rather than exclusive" to the consumer protection laws of other states.  
3 (Doc. no. 157-1 at 43-44; doc. no. 185 at 35.) Plaintiffs cite no binding authority  
4 for this proposition. The California appellate cases they cite do not conclude there  
5 are no material differences. *See Wershba v. Apple Computer, Inc.*, 91 Cal. App.  
6 4th 224, 242 (2001) ("California consumer protection laws are among the strongest  
7 in the country."); *Clothesrigger, Inc. v. GTE Corp.*, 191 Cal. App. 3d 605, 616  
8 (1987) ("California's more favorable laws may properly apply to benefit  
9 nonresident plaintiffs when their home states have no identifiable interest in  
10 denying such persons full recovery."). *Wershba* approved a class-wide settlement  
11 of a California unfair business practice claim across a nationwide class because,  
12 notwithstanding the differences in the consumer protection laws of various states,  
13 "this is not necessarily fatal to a finding that there is a predominance of common  
14 issues among a nationwide class." 91 Cal. App. 4th at 244. *Clothesrigger* held  
15 that the trial court did not make the findings required by the governmental interest  
16 analysis and remanded for findings. 191 Cal. App. 3d at 613-16, 619-20. The  
17 differences among state consumer protection laws, for example, in the requirement  
18 of defendant's intent or knowledge, or a statute of limitations that is shorter than  
19 California's, are material. *See Mazza*, 666 F.3d at 590-91; *see also McCann v.*  
20 *Foster Wheeler LLC*, 48 Cal.4th 68, 88-90 (2010) (statute of repose under foreign  
21 law would bar the action).

22       If there is a material difference, the foreign law proponent must next  
23 establish the foreign "jurisdiction's interest in the application of its own law *under*  
24 *the circumstances of the particular case*" to show that "a true conflict exists."  
25 *Mazza*, 666 F.3d at 590 (quoting *McCann*, 48 Cal.4th at 90) (emphasis added).  
26 Defendant does not analyze the state interests under the circumstances of this  
27 particular case, but points to the findings made in *Mazza*. (Doc. no. 170-1 at 36.)  
28

1 *Mazza* observed that in the false advertising context, "[e]very state has an interest  
2 in having its law applied to its resident claimants," 666 F.3d at 591-92 (internal  
3 quotation marks, brackets and citation omitted); "each state has an interest in  
4 setting the appropriate level of liability for companies conducting business within  
5 its territory," *id.* (citing *McCann*, 48 Cal.4th at 91); and "[e]ach state has an interest  
6 in balancing the range of products and prices offered to consumers with the legal  
7 protections afforded them," *id.* *Mazza* concluded that it was error to "discount[] or  
8 not recogniz[e] each state's valid interest in shielding out-of-state businesses from  
9 what the state may consider to be excessive litigation." *Id.* These interests are  
10 valid for any state. Based on the foregoing, in a case where a plaintiff seeks to  
11 apply California consumer protection law to a California corporation on behalf of  
12 foreign citizens who purchased defendant's products outside California, a true  
13 conflict arises where California law affords either greater or lesser consumer  
14 protection because other states may choose to offer lesser consumer protection and  
15 a more business-friendly climate than California, while others may offer more  
16 consumer protection and a less business-friendly environment.

17 Third, if the court finds that there is a true conflict, it carefully  
18 evaluates and compares the nature and strength of the interest of each  
19 jurisdiction in the application of its own law to determine which  
20 state's interest would be more impaired if its policy were subordinated  
21 to the policy of the other state, and then ultimately applies the law of  
22 the state whose interest would be more impaired if its law were not  
23 applied.

23 *Mazza*, 666 F.3d at 590 (quoting *McCann*, 48 Cal.4th at 82 (citations and quotation  
24 marks omitted)). In making this analysis,

25 the court does not "weigh" the conflicting governmental interests in  
26 the sense of determining which conflicting law manifested the 'better'  
27 or the 'worthier' social policy on the specific issue. An attempted  
28 balancing of conflicting state policies in that sense is difficult to  
justify in the context of a federal system in which, within

1 constitutional limits, states are empowered to mold their policies as  
2 they wish. Instead, the process can accurately be described as a  
3 problem of allocating domains of law-making power in multi-state  
4 contexts—by determining the appropriate limitations on the reach of  
5 state policies—as distinguished from evaluating the wisdom of those  
6 policies. Emphasis is placed on the appropriate scope of conflicting  
7 state policies rather than on the 'quality' of those policies.

7 *McCann*, 48 Cal.4th at 97 (internal quotation marks, brackets, ellipses and citation  
8 omitted); *see also Mazza*, 666 F.3d at 593.

9 Defendant does not offer an analysis of its own, but relies entirely on the  
10 holding in *Mazza*: "because the interests of those other states in applying their own  
11 laws to their own consumers is stronger than California's 'attenuated' interest, the  
12 Ninth Circuit held that 'each class member's consumer protection claim should be  
13 governed by the consumer protection laws of the jurisdiction where the transaction  
14 took place.'" (Doc. no. 170-1 at 36 (quoting *Mazza*, 666 F.3d at 594).)

15 California legislature expressed a strong interest in regulating false  
16 advertising which emanates from California into other states. It is unlawful under  
17 the UCL and FAL to make or disseminate a false or misleading statement "or cause  
18 [it] to be made or disseminated before the public in this state, or to make or  
19 disseminate [it] or cause [it] to be made or disseminated *from this state before the*  
20 *public in any state.*" Cal. Bus. & Prof. Code §§ 17500, 17200 (incorporates §  
21 17500 by reference). Under the facts of the pending case, applying these  
22 provisions to out-of-state sales is consistent with the principle that "a jurisdiction  
23 ordinarily has the predominant interest in regulating conduct that occurs within its  
24 borders . . ." *McCann*, 48 Cal.4th at 97-98 (internal quotation marks and citations  
25 omitted).

26 Based on this principle, *McCann* and *Mazza* found foreign law applicable to  
27 their facts. In *Mazza*, the defendant, American Honda Motor Company, was  
28

1 headquartered in California and its advertising agency, which produced the  
2 allegedly misleading materials, was located in California. However, the  
3 advertising campaign, as it pertained to the relevant representations, was "very  
4 limited," and it was "likely that many class members were never exposed to the  
5 allegedly misleading advertisements." *Mazza*, 666 F.3d at 595. In *Mazza*, whether  
6 a purchaser was exposed to the allegedly misleading statement depended in large  
7 part on whether the ultimate seller chose to present it, for example, when the  
8 representations were made in product brochures, Acura Style magazine, video or  
9 other presentations, which were available only at dealerships. *Id.* at 586-87  
10 (through "small scale marketing efforts," dealers were "encouraged" to show  
11 promotional materials at dealership kiosks). Accordingly, "the communication of  
12 the advertisements to the claimants and their reliance thereon in purchasing  
13 vehicles--took place in the various foreign states, not in California." *Id.* at 594. In  
14 this regard, the Court concluded,

15 We recognize that California has an interest in regulating those who  
16 do business within its state boundaries, . . . , but we disagree with the  
17 dissent that applying California law to the claims of foreign residents  
18 *concerning acts that took place in other states where cars were  
purchased or leased* is necessary to achieve that interest in this case.

19 *Id.* (emphasis added).

20 *Mazza* relies in large part on *McCann*, 48 Cal.4th 68 (2010), because the  
21 choice of law issue is governed by California law. *Mazza*, 666 F.3d at 589.  
22 *McCann* decided that foreign law applied because the incident occurred in  
23 Oklahoma when the plaintiff was an Oklahoma resident and the defendant was  
24 conducting business in Oklahoma. 48 Cal.4th at 98. The fact that the defendant  
25 was a New York company was not persuasive, because Oklahoma had an interest  
26 in promoting business, whether by domestic or foreign companies. *Id.* at 97. The  
27 fact that the plaintiff later moved to California for unrelated reasons was  
28



1 happenstance that should not determine the choice of law. *Id.* The Court  
2 recognized that the outcome could be different, if the defendant's conduct occurred  
3 in California:

4 California's interest in applying its laws providing a remedy to, or  
5 facilitating recovery by, a potential plaintiff in a case in which the  
6 defendant's allegedly tortious conduct occurred in another state is less  
7 than its interest when the defendant's conduct occurred in California.

8 *Id.* at 99.

9 In the pending case, the alleged misconduct occurred entirely in California.  
10 (*See Schrententhaler Depo.* at 60-61.) All allegedly false representations were  
11 made on Defendant's product labels, and all products were sold with labels. All  
12 final decisions regarding the labels were made and approvals were given in  
13 California, where Defendant is incorporated and maintains its principal place of  
14 business. Defendant distributed its products nationwide.

15 The fact that some products were purchased in one state rather than another  
16 should be immaterial to the choice of law under the facts of the present case,  
17 because the alleged misconduct occurred entirely in California. Defendant points  
18 to no state with a greater interest in enforcing its laws under the facts of this case.  
19 Applying the UCL and FAL nationwide does not impede other states in applying  
20 their policies, whether through consumer-friendly or business-friendly legislation,  
21 to the conduct that occurs within their borders. In light of the foregoing,  
22 Defendant has provided no grounds to conclude that any other state's interest,  
23 including any state's "interest in promoting business," *Mazza*, 666 F.3d at 593,  
24 would be more impaired than California's, if California law did not apply.

25 Defendant's argument that the questions of law presented by each state's own  
26 consumer protection laws defeat a showing of commonality and predominance is  
27 rejected. For the reasons stated above, and in the context of California consumer  
28

1 protection claims, Plaintiffs meet the commonality and predominance requirements  
2 for the UCL and FAL claims on a nationwide basis to the extent they are based on  
3 statements of protein content on protein shake labels and "lean" statements on  
4 protein powder labels.

### 5                   **3.     Typicality**

6           The typicality requirement of Rule 23(a)(3) focuses on the relationship of  
7 facts and issues between the class and its representatives.

8           [T]he commonality and typicality requirements of Rule 23(a) tend to  
9 merge. Both serve as guideposts for determining whether under the  
10 particular circumstances maintenance of a class action is economical  
11 and whether the named plaintiff's claim and the class claims are so  
12 interrelated that the interests of the class members will be fairly and  
adequately protected in their absence.

13 *Dukes*, 564 U.S. at 249 n.5 (internal quotation marks and citation omitted).

14 "[R]epresentative claims are 'typical' if they are reasonably co-extensive with those  
15 of absent class members; they need not be substantially identical." *Hanlon v.*  
16 *Chrysler Corp.*, 150 F.3d 1011, 1020 (9th Cir. 1998).

17           The test of typicality is whether other members have the same or  
18 similar injury, whether the action is based on conduct which is not  
19 unique to the named plaintiffs, and whether other class members have  
20 been injured by the same course of conduct.

21 *Wolin v. Jaguar Land Rover N. Am., LLC*, 617 F.3d 1168, 1175 (9th Cir. 2010)  
22 (internal quotation marks and citations omitted).

23           Defendant does not dispute that Plaintiffs' claims are typical of the class  
24 members' claims. Plaintiffs and putative class members were injured by the same  
25 conduct -- Defendant's allegedly misleading statements on product labels. The  
26 relevant conduct is not unique to named Plaintiffs. The legal theories Plaintiffs

27 /////  
28

1 seek to assert on behalf of the class apply equally to Plaintiffs and the class  
2 members. Plaintiffs therefore meet the typicality requirement.

#### 3 **4. Adequacy**

4 Rule 23(a)(4) requires a showing that "the representative parties will fairly  
5 and adequately protect the interests of the class." Fed. R. Civ. P. 23(a)(4). This  
6 requirement is grounded in constitutional due process concerns: "absent class  
7 members must be afforded adequate representation before entry of judgment which  
8 binds them." *Hanlon*, 150 F.3d at 1020. In reviewing this issue, courts must  
9 resolve two questions: "(1) do the named plaintiffs and their counsel have any  
10 conflicts of interest with other class members, and (2) will the named plaintiffs and  
11 their counsel prosecute the action vigorously on behalf of the class?" *Id.* In other  
12 words, the named plaintiffs and their counsel must have sufficient "zeal and  
13 competence" to protect the interests of the rest of the class. *Fendler v. Westgate-*  
14 *California Corp.*, 527 F.2d 1168, 1170 (9th Cir. 1975).

15 Defendant does not dispute that the adequacy requirement is met. No  
16 conflict of interest is apparent from the record between Plaintiffs and their counsel  
17 on one hand and the putative class on the other.

18 With respect to Plaintiffs, the issue is whether they "maintain a sufficient  
19 interest in, and nexus with, the class so as to ensure vigorous representation." *In re*  
20 *Online DVD Rental Antitrust Litig.*, 779 F.3d 934, 943 (9th Cir. 2015) (internal  
21 quotation marks, brackets and citation omitted). Based on Plaintiffs' declarations,  
22 they have suffered the same injury as they allege on behalf of the class, understand  
23 their duties if appointed class representatives, and are willing to undertake them,  
24 including vigilantly prosecuting the case on behalf of the class. To date, Plaintiffs  
25 have been actively involved in the prosecution of this action, including providing  
26 information to class counsel, participating in written discovery and giving  
27 deposition testimony. They intend to continue to actively prosecute the case on  
28

1 behalf of the class. (Doc. no. 157-2 ("Roman Decl."); 157-3 ("Clay Decl."); 157-4  
2 ("Reichert Decl."); 157-5 ("Ehrlichman Decl.")) Although Plaintiff Christopher  
3 Roman has criminal history, Defendant does not contend he cannot adequately  
4 represent the class. Roman's history does not include crimes which would  
5 adversely reflect on his credibility. (*See* Deposition of Christopher Roman  
6 ("Roman Depo.") at 12-18.)<sup>16</sup> Plaintiffs therefore meet Rule 23(a)(4) adequacy  
7 requirements.

8 Based on the counsels' declarations, California attorneys Jeffrey R. Krinsk  
9 and Trenton Kashima, as well as Michigan attorneys Nick Suciu III, Jason J.  
10 Thompson, and Amy L. Marino meet Rule 23(a)(4) adequacy requirements and  
11 Rule 23(g) requirements for appointment of class counsel. (Doc. no. 157-9 ("Suciu  
12 Decl."), 157-10 ("Thompson Decl."), 157-11 ("Krinsk Decl."), 157-11 (Ex. A to  
13 Krinsk Decl.), 157-13 ("Marino Decl.") at 2).

14 **B. Rule 23(b)(3) Requirements**

15 Certification under Rule 23(b)(3) is proper when "the questions of law or  
16 fact common to class members predominate over any questions affecting only  
17 individual members, and . . . a class action is superior to other available methods  
18 for fairly and efficiently adjudicating the controversy." Fed. R. Civ. Proc.  
19 23(b)(3).

20 As discussed above, this action meets the predominance requirement. The  
21 superiority requirement includes consideration of:

- 22 (A) the class members' interests in individually controlling the  
23 prosecution or defense of separate actions;  
24 (B) the extent and nature of any litigation concerning the controversy  
already begun by or against class members;

25 //

26  
27 <sup>16</sup> Excerpts from the Roman Depo. were filed as doc. no. 170-6 at 189-221, and  
28 doc. no. 185-8.

1 (C) the desirability or undesirability of concentrating the litigation of  
2 the claims in the particular forum; and  
3 (D) the likely difficulties in managing a class action.

4 Fed. R. Civ. Proc. 23(b)(3). This inquiry "requires the court to determine whether  
5 maintenance of this litigation as a class action is efficient and whether it is fair,"  
6 such that the proposed class is superior to other methods for adjudicating the  
7 controversy. *Wolin*, 617 F.3d at 1175-76.

8 Defendant argues class action is not superior because individual issues  
9 predominate and there are material differences among state consumer protection  
10 laws. (Doc. no. 170-1 at 58-59.) Defendant also contends that "Plaintiffs have not  
11 offered any means [to] exclude uninjured class members." (*Id.* at 58 (citing *Chow*  
12 *v. Neutrogena Corp.*, 2013 WL 5629777 \*2 (C.D. Cal. Jan. 22, 2013).) The latter  
13 argument is based on the contention that each class member may not have been  
14 exposed to the allegedly misleading advertisements, and therefore would not suffer  
15 the same injury. *See Chow*, 2013 WL 5629777 \*1-2. All of Defendant's  
16 arguments were rejected in the context of analyzing the predominance requirement.

17 This is a consumer class action involving low-priced consumer goods and a  
18 large number of potential class members. Prosecution of the alleged claims  
19 requires discovery, including product testing, and expert analysis, including  
20 consumer surveys. It would therefore most likely not be feasible for class  
21 members to individually prosecute the consumer protection claims asserted herein.  
22 *See Briseno*, 844 F.3d at 1129. The class members' interest in individually  
23 controlling the prosecution of individual actions is small. According to Plaintiffs,  
24 no other similar cases are pending. (Doc. no. 157-1 at 41.)

25 This action bears a substantial connection to California, as Defendant is  
26 located in California (Schrententhaler Depo. at 61), two of the named Plaintiffs, as  
27 well as numerous other consumers, purchased Defendant's products during the  
28

1 class period in California (*see* Clay Decl. at 2; Roman Decl. at 2). The record does  
2 not reflect any reason not to concentrate the litigation of the claims in this District.  
3 Finally, it does not appear that this action will be more difficult to manage than  
4 other class actions.

5 For the foregoing reasons, the Court finds that all requirements for class  
6 action certification under Rule 23(b)(3) are met with respect to (1) the nationwide  
7 classes as to the UCL and FAL claims to the extent they are based on statements of  
8 protein content on protein shake labels and "lean" statements on protein powder  
9 labels; (2) the California subclasses as to the UCL, FAL and CLRA claims to the  
10 extent they are based on statements of protein content on protein shake labels; and  
11 UCL and FAL claims to the extent they are based on "lean" statements on protein  
12 powder labels; (3) the Florida subclasses as to the FDUTPA violation based on the  
13 protein content statements on protein shakes and "lean" statements on protein  
14 powders; and (4) the Michigan subclass as to the MCPA violation based on the  
15 protein content statements on protein shakes.

### 16 **III. CONCLUSION**

17 1. Plaintiffs' motion for class certification is granted in part and denied in  
18 part. The following classes are certified:

19 (a) A nationwide class comprising of all persons in the United  
20 States who, within four (4) years of the filing of this action, purchased Defendant's  
21 Cytosport Whey Isolate Protein Drink; Monster Milk: Protein Power Shake;  
22 Genuine Muscle Milk: Protein Nutrition Shake; and Muscle Milk Pro Series 40:  
23 Mega Protein Shake. The class is certified for purposes of prosecuting violations  
24 of the California Unfair Competition Law, Cal. Bus. & Prof. Code §§ 17200 *et*  
25 *seq.*, and California False Advertising Law, Cal. Bus. & Prof. Code §§ 17500 *et*  
26 *seq.*, to the extent the claims are based on the protein content statements on product  
27 labels.

1 (b) A nationwide class comprising of all persons in the United  
2 States who, within four (4) years of the filing of this action, purchased Defendant's  
3 Muscle Milk: Lean Muscle Protein Powder; Muscle Milk Light: Lean Muscle  
4 Protein Powder; Muscle Milk Naturals: Nature's Ultimate Lean Muscle Protein;  
5 Muscle Milk Gainer; High Protein Gainer Powder Drink Mix; Muscle Milk Pro  
6 Series 50: Lean Muscle Mega Protein Powder (14 oz. to 10 lbs. products); and  
7 Monster Milk: Lean Muscle Protein Supplement (2.06 and 4.13 lbs. products).  
8 The class is certified for purposes of prosecuting violations of the California Unfair  
9 Competition Law, Cal. Bus. & Prof. Code §§ 17200 *et seq.*, and California False  
10 Advertising Law, Cal. Bus. & Prof. Code §§ 17500 *et seq.*, to the extent the claims  
11 are based on the "lean" statements on product labels.

12 (c) All persons residing in California who, within four (4) years of  
13 the filing of this action, purchased Defendant's Cytosport Whey Isolate Protein  
14 Drink; Monster Milk: Protein Power Shake; Genuine Muscle Milk: Protein  
15 Nutrition Shake; and Muscle Milk Pro Series 40: Mega Protein Shake. The class is  
16 certified for purposes of prosecuting violations of the California Unfair  
17 Competition Law, Cal. Bus. & Prof. Code §§ 17200 *et seq.*, California False  
18 Advertising Law, Cal. Bus. & Prof. Code §§ 17500 *et seq.*, and California  
19 Consumer Legal Remedies Act, Cal. Civ. Code § 1770(a)(5), to the extent the  
20 claims are based on the protein content statements on product labels.

21 (d) All persons residing in California who, within four (4) years of  
22 the filing of this action, purchased Defendant's Muscle Milk: Lean Muscle Protein  
23 Powder; Muscle Milk Light: Lean Muscle Protein Powder; Muscle Milk Naturals:  
24 Nature's Ultimate Lean Muscle Protein; Muscle Milk Gainer; High Protein Gainer  
25 Powder Drink Mix; Muscle Milk Pro Series 50: Lean Muscle Mega Protein  
26 Powder (14 oz. to 10 lbs. products); and Monster Milk: Lean Muscle Protein  
27 Supplement (2.06 and 4.13 lbs. products). The class is certified for purposes of  
28

1 prosecuting violations of the California Unfair Competition Law, Cal. Bus. & Prof.  
2 Code §§ 17200 *et seq.*, and California False Advertising Law, Cal. Bus. & Prof.  
3 Code §§ 17500 *et seq.*, to the extent the claims are based on the "lean" statements  
4 on product labels.

5 (e) All persons residing in Florida who, within four (4) years of the  
6 filing of this action, purchased Defendant's Cytosport Whey Isolate Protein Drink;  
7 Monster Milk: Protein Power Shake; Genuine Muscle Milk: Protein Nutrition  
8 Shake; and Muscle Milk Pro Series 40: Mega Protein Shake. The class is certified  
9 for purposes of prosecuting violations of the Florida Deceptive and Unfair Trade  
10 Practices Act, Fla. Stat. §§ 501.201 *et seq.*, to the extent the claim is based on the  
11 protein content statements on product labels.

12 (f) All persons residing in Florida who, within four (4) years of the  
13 filing of this action, purchased Defendant's Muscle Milk: Lean Muscle Protein  
14 Powder; Muscle Milk Light: Lean Muscle Protein Powder; Muscle Milk Naturals:  
15 Nature's Ultimate Lean Muscle Protein; Muscle Milk Gainer; High Protein Gainer  
16 Powder Drink Mix; Muscle Milk Pro Series 50: Lean Muscle Mega Protein  
17 Powder (14 oz. to 10 lbs. products); Monster Milk: and Lean Muscle Protein  
18 Supplement (2.06 and 4.13 lbs. products). The class is certified for purposes of  
19 prosecuting violations of the Florida Deceptive and Unfair Trade Practices Act,  
20 Fla. Stat. §§ 501.201 *et seq.*, to the extent the claim is based on "lean" statements  
21 on product labels.

22 (g) All persons residing in Michigan who, within six (6) years of  
23 the filing of this action, purchased Defendant's Cytosport Whey Isolate Protein  
24 Drink; Monster Milk: Protein Power Shake; Genuine Muscle Milk: Protein  
25 Nutrition Shake; and Muscle Milk Pro Series 40: Mega Protein Shake. The class is  
26 certified for purposes of prosecuting violations of the Michigan Consumer

27 //



1 Protection Act, Mich. Comp. Laws § 445.903(1)(c), to the extent the claim is based  
2 on protein content statements on product labels.

3 2. Excluded from the above classes are: (a) Defendant and any entity in  
4 which Defendant has or had a controlling interest; (b) the officers and directors of  
5 Defendant at all relevant times, the members of Defendant's officers' and directors'  
6 immediate families and their legal representatives, heirs, successors, or assigns; (c)  
7 any judge to whom this action is assigned, any members of such judges' staffs, and  
8 any members of such judges' immediate families; and (4) all persons or entities that  
9 purchased the relevant products for purposes of resale.

10 3. Plaintiffs Chayla Clay, Chris Roman, Erica Ehrlichman, and Logan  
11 Reichert are appointed as class representatives for the nationwide classes. In  
12 addition, Plaintiffs Chayla Clay and Chris Roman are appointed as class  
13 representatives for the California classes, Plaintiff Logan Reichert is appointed as  
14 class representative for the Florida classes, and Plaintiff Erica Ehrlichman is  
15 appointed as class representative for the Michigan class.

16 4. Attorneys Jeffrey R. Krinsk, Trenton Kashima, Nick Suciu III, Jason  
17 J. Thompson, and Amy L. Marino are appointed as class counsel under Rule 23(g).

18 5. No later than September 14, 2018, the parties shall jointly propose a  
19 class notice in compliance with Federal Rule of Civil Procedure 23(c)(2)(B).

20 6. Defendant's *Daubert* motion is granted with respect to the opinion of  
21 Elizabeth Howlett, Ph.D. that the statements on protein powder labels regarding

22 //

23

24

25

26

27

28

1 L-glutamine were material. The opinion is excluded for purposes of this Order  
2 only. Defendant's motion is denied in all other respects.

3 **IT IS SO ORDERED.**

4  
5 Dated: September 7, 2018

6 

7 Hon. M. James Lorenz  
8 United States District Judge  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28